T0	Participants 56 129	metastatic and/or unresectable malignant gastrointestinal stromal tumors.
T1	Participants 351 455	patients with CD117(+) unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs).
T2	Participants 606 656	patients with progressive disease on a lower dose.
T3	Participants 793 918	European Organization for Research and Treatment of Cancer (n = 946) and the other by the Southwest Oncology Group (n = 746).